TCT 782: Post-Procedural Residual MR But Not Mean Gradient Predicts Long-Term Clinical Outcomes in Real-World Patients Undergoing Mitral TEER for Primary MR: Insights from the PRIME-MR Registry

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Bayer AG; NVT
• Grant Support/Research Contract - German Heart Foundation (DHS)